1- Department of Population and Health, National Institute for Population Research, Tehran, Iran
2- Department of Demography, Faculty of Social Sciences, University of Tehran, Tehran, Iran
3- Ministry of Science, Research and Technology, Tehran, Iran
2- Department of Demography, Faculty of Social Sciences, University of Tehran, Tehran, Iran
3- Ministry of Science, Research and Technology, Tehran, Iran
Abstract: (30 Views)
Objective(s): In developing countries, including Iran, premature mortality imposes a significant economic burden on these countries through lost productivity. Accordingly, this study tried to calculate the economic consequences of premature deaths caused by the main causes of death in Iran in 2021.
Methods: This was a cross-sectional, quantitative and analytical study that was conducted using secondary data. For data analysis, all deaths in Iran were considered according to age, gender and cause of death in 2021. The data used in this research was taken from the Global Burden of Disease Study. This study has followed the quantification of the economic burden of the main causes of premature death in Iran using the human capital approach.
Results: The economic cost of premature death in Iran in 2021 accounted for about 1% of the GDP. The results of the research indicated a high contribution of men in the lost productivity in Iran, and also according to the time period studied in this research, the covid-19 disease had a great impact on premature mortality and increased lost productivity of the active population of Iran. Among other noteworthy results of this study was the economic cost of deaths caused by traffic accidents that target the young group of the population. The age group of 35 to 39 years had the largest share of lost productivity due to this cause, and these accidents accounted for 10% of the economic costs of premature death in men.
Conclusion: The findings of this study suggest that sufficient resources should be allocated for healthcare and treatment and investment should be made in preventive and primary care in order to prevent avoidable deaths through treatment and prevention.
Methods: This was a cross-sectional, quantitative and analytical study that was conducted using secondary data. For data analysis, all deaths in Iran were considered according to age, gender and cause of death in 2021. The data used in this research was taken from the Global Burden of Disease Study. This study has followed the quantification of the economic burden of the main causes of premature death in Iran using the human capital approach.
Results: The economic cost of premature death in Iran in 2021 accounted for about 1% of the GDP. The results of the research indicated a high contribution of men in the lost productivity in Iran, and also according to the time period studied in this research, the covid-19 disease had a great impact on premature mortality and increased lost productivity of the active population of Iran. Among other noteworthy results of this study was the economic cost of deaths caused by traffic accidents that target the young group of the population. The age group of 35 to 39 years had the largest share of lost productivity due to this cause, and these accidents accounted for 10% of the economic costs of premature death in men.
Conclusion: The findings of this study suggest that sufficient resources should be allocated for healthcare and treatment and investment should be made in preventive and primary care in order to prevent avoidable deaths through treatment and prevention.
type of study: Descriptive |
Subject:
Health Economic
Received: 2024/09/30 | Accepted: 2025/07/30 | ePublished ahead of print: 2026/01/28
Received: 2024/09/30 | Accepted: 2025/07/30 | ePublished ahead of print: 2026/01/28
References
1. Gardner JW, Sanborn JS. Years of potential life lost (YPLL) -what does it measure. Epidemiology 1990; 1: 322-329 [DOI:10.1097/00001648-199007000-00012]
2. Fernandes NM, Silva JSGS, Varela DV, Lopes ED, Soares J. The economic impact of premature mortality in Cabo Verde: 2016-2020. PLoS ONE 2023; 18: 2785-90 [DOI:10.1371/journal.pone.0278590]
3. Burnet NG, Jefferies SJ, Benson RJ, Hunt DP, Treasure FP. Years of life lost (YLL) from cancer is an important measure of population burden-and should be considered when allocating research funds. British Journal of Cancer 2005; 92: 241-245 [DOI:10.1038/sj.bjc.6602321]
4. Rumisha SF, George J, Bwana VM, Mboera LEG. Years of potential life lost and productivity costs due to premature mortality from six priority diseases in Tanzania, 2006-2015. PLoS One 2020;15:1-18 [DOI:10.1371/journal.pone.0234300]
5. Dı'az-Jime'nez D, Castañeda-Orjuela C, Castillo-Rodrı'guez L, De la Hoz-Restrepo F. Economic costs analysis of the avoidable mortality in Colombia 1998-2011. Values in Health Regional Issues 2015; 8: 129-135 [DOI:10.1016/j.vhri.2015.08.007]
6. Ortiz-Ortiz K, Pe' rez-Irizarry J, Marı'n-Centeno H, Ortiz A, Torres-Cintro'n M, Torres-Berrios N. Productivity loss in Puerto Rico's labor market due to cancer mortality. Puerto Rico Health Sciences Journal 2010; 29:241-249
7. Hanly PA, Sharp L. The cost of lost productivity due to premature cancer-related mortality: an economic measure of the cancer burden. BMC Cancer 2014; 14: 224-231 [DOI:10.1186/1471-2407-14-224]
8. Jiang S, Wang Y, Si L, Zang X, Gu YY, Jiang Y, Liu GG, Wu J. Incorporating productivity loss in health economic evaluations: a review of guidelines and practices worldwide for research agenda in China. BMJ Glob Health. 2022;7:1-14 [DOI:10.1136/bmjgh-2022-009777]
9. Pham TM, Shack L, Cheung W Y. Introduction of a novel measure of premature mortality caused by chronic condition: real-world examples from prostate and testis cancers in Canada, 1980-2015. Annals of Epidemiology 2019; 37: 81-83 [DOI:10.1016/j.annepidem.2019.07.011]
10. Joel GR. Editorial reducing premature mortality among young and middle-aged adults. Health Promotion and Chronic Disease Prevention in Canada: Research, Policy and Practice 2017; 37: 27-32 [DOI:10.24095/hpcdp.37.3.01]
11. Changik Jo. Cost-of-illness studies: concepts, scopes, and methods. Clinical and Molecular Hepatology 2014; 20: 327-337 [DOI:10.3350/cmh.2014.20.4.327]
12. Khorasani S, Rezaei S, Rashidian H, Daroudi R. Years of potential life lost and productivity costs due to premature cancer-related mortality in Iran. Asian Pacific Journal of Cancer 2015; 16: 1845-1850 [DOI:10.7314/APJCP.2015.16.5.1845]
13. Nahvijou A, Daroudi R, Javan-Noughabi J, Dehdarirad H, Faramarzi A. The Lost Productivity Cost of Premature Mortality Owing to Cancers in Iran: Evidence from the GLOBOCAN 2012 to 2018 Estimates. Value Health Regional Issues 2022;31:1-9 [DOI:10.1016/j.vhri.2022.02.002]
14. GBD 2019 Diseases and Injuries Collaborators. Global burden of 369 diseases and injuries in 204 countries and territories, 1990-2019: a systematic analysis for the Global Burden of Disease Study 2019. Lancet 2020;396:1204-1222 [DOI:10.1016/S0140-6736(20)30925-9]
15. Olivera MJ, Palencia-Sa'nchez F, Riaño-Casallas M. The cost of lost productivity due to premature chagas disease-related mortality: lessons from Colombia (2010-2017). Trop Medical Infectious Disease 2021; 6:17-25 [DOI:10.3390/tropicalmed6010017]
16. Abdoli, G. Estimation of social discount rate for Iran. Economics Research 2009;34:135-156 [Persian]
17. Menzin, J, Marton, JP, Menzin JA. Lost productivity due to premature mortality in developed and emerging countries: an application to smoking cessation. Med Research Methodology 2012;7:12-87 [DOI:10.1186/1471-2288-12-87]
18. Daneshmand A, Jahangard E, Abdollah-Milani M. A time preference measure of the social discount rate for Iran. Journal of Economic Structures 2018; 7: 1-10 [DOI:10.1186/s40008-018-0127-x]
19. Goeree R, O'Brien BJ, Blackhouse G, Agro K, Goering P. The valuation of productivity costs due to premature mortality: a comparison of the human-capital and friction-cost methods for schizophrenia. The Canadian Journal of Psychiatry 1999; 44: 455-463 [DOI:10.1177/070674379904400505]
20. Łyszczarz B. Production losses associated with premature mortality in 28 European :union: countries. J Glob Health 2019; 9: 204-218 [DOI:10.7189/jogh.09.020418]
21. Najafi F, Karami-Matin B, Rezaei S, Khosravi A, Soofi M. Productivity costs and years of potential life lost associated with five leading causes of death: Evidence from Iran (2006-2010). Medical Journal Islamic Republic of Iran 2021; 30:412- 420
22. Olshansky J. Ault A. The fourth stage of the epidemiologic transition: the age of delayed degenerative diseases. Milbank 1986; 64: 355-91 [DOI:10.2307/3350025]
23. Omran A. The epidemiologic transition: A theory of the epidemiology of population change. Milbank Memorial Fund Quarterly 1971; 49: 509-538 [DOI:10.2307/3349375]
24. Chen J. Pathogenicity and transmissibility of 2019-CoV-a quick overview and comparison with other emerging viruses. Microbes and Infection 2022; 22: 69-71 [DOI:10.1016/j.micinf.2020.01.004]
25. Mobaraki K, Jamal A. Emerging diseases as a challenge for epidemiological transition in this global village. Biomedical Journal of Scientific and Technical Research 2020; 25: 4-20 [DOI:10.26717/BJSTR.2020.25.004244]
Send email to the article author
| Rights and Permissions | |
 |
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License. |